These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 148118)

  • 1. Biochemical changes noted during intermittent administration of streptokinase.
    Verstraete M; Vermylen J; Schetz J
    Thromb Haemost; 1978 Feb; 39(1):61-8. PubMed ID: 148118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intermittent plasminogen-streptokinase treatment of deep vein thrombosis.
    Scully MF; Lane DA; Sagar S; Thomas DP; Kakkar VV
    Thromb Haemost; 1977 Feb; 37(1):162-9. PubMed ID: 138963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasmin inhibitors and fibrinogen breakdown during the initial phase of thrombolytic treatment--the problem of the alpha 2-antiplasmin determination.
    Noll G; Lämmle B; Duckert F
    Thromb Haemost; 1984 Jul; 51(3):334-7. PubMed ID: 6238441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrinolytic profiles in local low-dose thrombolysis with streptokinase and recombinant tissue plasminogen activator.
    Berridge DC; Earnshaw JJ; Westby JC; Makin GS; Hopkinson BR
    Thromb Haemost; 1989 Apr; 61(2):275-8. PubMed ID: 2501898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LYS-plasminogen shortens the duration of local thrombolytic treatment of peripheral arterial occlusions--a randomized controlled trial.
    Poredos P; Videcnik V
    Wien Klin Wochenschr; 1999 Jan; 111(1):21-5. PubMed ID: 10067266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrinolytic treatment by infusion of streptokinase-plasminogen-complex (activator): laboratory effects.
    Martin H; Auel H; Riedel C
    Behring Inst Mitt; 1986 Feb; (79):263-71. PubMed ID: 2424424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies on the medical treatment of deep vein thrombosis.
    Schulman S
    Acta Med Scand Suppl; 1985; 704():1-68. PubMed ID: 3913282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic fibrinolytic activity and inhibitor levels during treatment of deep vein thrombosis with urokinase and streptokinase.
    Theiss W; Asbeck F; Kriessmann A; Trübestein G; Knoch K; de Swart CA; Marbert GA; van de Loo JC
    Thromb Haemost; 1983 Oct; 50(3):664-8. PubMed ID: 6196852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Haemorrhagic complications using streptokinase during 98 treatments. Place of the biological surveillance (author's transl)].
    Conard J; Samama M; Milochevitch R; Horellou MH; Chabrun B; Prestat J
    Nouv Presse Med; 1979 Apr; 8(16):1319-25. PubMed ID: 482100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Continuous intravenous infusion versus intermittent administration of streptokinase in patients with deep venous thrombosis of the lower extremity].
    Lopaciuk S; Meissner AJ; Ziemski JM; Tokarz A; Psuja P; Zawilska K; Głowiński S; Wołczyński Z; Czestochowska E; Tymiński W
    Pol Tyg Lek; 1991 Sep 9-30; 46(37-39):704-7. PubMed ID: 1669137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conjunctive administration of intravenous heparin attenuates cross-linked fibrin degradation in patients treated with streptokinase.
    Galvani M; Abendschein DR; Ferrini D; Ottani F; Rusticali F; Eisenberg PR
    Thromb Haemost; 1996 Sep; 76(3):339-43. PubMed ID: 8883267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The significance of changes in fibrinogen levels during thrombolytic therapy in myocardial infarct].
    Malý J; Pecka M; Pidrman V; Hamet A; Gregor J; Vodicka L; Siroký O; Tichý M
    Vnitr Lek; 1991 Mar; 37(3):229-37. PubMed ID: 2031311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequence of fibrinogen proteolysis and platelet release after intrauterine infusion of hypertonic saline.
    Nossel HL; Wasser J; Kaplan KL; LaGamma KS; Yudelman I; Canfield RE
    J Clin Invest; 1979 Nov; 64(5):1371-8. PubMed ID: 500818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intermittent plasminogen-streptokinase treatment of deep vein thrombosis.
    Kakkar VV; Scully MF
    Haemostasis; 1988; 18 Suppl 1():127-38. PubMed ID: 3350394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical comparison of intermittent streptokinase and intermittent streptokinase plasminogen therapy.
    Barlow GH; Kakkar VV; Bentley PG; Chan PS; Jones NA; Mistry FD
    Thromb Res; 1979; 15(1-2):135-42. PubMed ID: 483271
    [No Abstract]   [Full Text] [Related]  

  • 16. Hemorrhage vs rethrombosis after thrombolysis for acute myocardial infarction.
    Timmis GC; Mammen EF; Ramos RG; Gordon S; Gangadharan V; Hauser AM; Westveer DC; Stewart JR
    Arch Intern Med; 1986 Apr; 146(4):667-72. PubMed ID: 3963947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Biological changes during the local administration of small doses of urokinase].
    Michaud A; Aiach M; Fiessinger JN; Vayssairat M; Juillet Y
    Nouv Presse Med; 1978 Oct; 7(35):3151. PubMed ID: 152910
    [No Abstract]   [Full Text] [Related]  

  • 18. The evaluation of plasmin and streptokinase activator complexes in a new rabbit model of venous thrombosis.
    Dupe RJ; English PD; Smith RA; Green J
    Thromb Haemost; 1981 Aug; 46(2):528-34. PubMed ID: 6458112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Deep venous thrombosis: streptokinase treatment with adaptation of the maintenance dosage].
    Theiss W; Hofer E; Kriessmann A; Lutilsky L; Sauer E; Wirtzfeld A
    Med Klin; 1980 Aug; 75(16):580-6. PubMed ID: 7412703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Systemic thrombolysis of arterial occlusions of the lower extremities. Comparison of various treatment schedules].
    Lämmle B; Noll G; Christe M; Fritschi J; Czendlik C; Marbet GA; Biland L; Da Silva A; Huber P; Widmer LK
    Schweiz Med Wochenschr; 1983 Oct; 113(43):1570-6. PubMed ID: 6227992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.